Stevens-Johnson induced by imiquimod 5% cream: a case report

Ilaria Trave; Ilaria Salvi; Claudia Micalizzi; Riccardo Castelli; Aurora Parodi; Emanuele Cozzani

doi:10.4081/dr.2024.9930

Authors

Ilaria Trave
ilaria.trave@unige.it
Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. https://orcid.org/0000-0002-5469-4517
Ilaria Salvi Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. https://orcid.org/0000-0003-0151-3126
Claudia Micalizzi Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Riccardo Castelli Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. https://orcid.org/0000-0002-7184-7888
Aurora Parodi Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. https://orcid.org/0000-0002-6622-2226
Emanuele Cozzani Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.

Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.

Cantisani C, Lazic T, Richetta AG, et al. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Disco 2012;6:65-9.

Nanda J, Bermudez R. Imiquimod. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557413/.

Camacho Molina A, Alarcón Manoja E, Corzo Gilabert JR, García Gil D. Erythema multiforme induced by topical imiquimod. Emergencias 2020;32:219.

Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas) 2021;57:895.

Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.

Shaw B, Madden M, Crespo A, et al. A Rare Case of Severe Stevens-Johnson Syndrome Triggered by Topical Ofloxacin. Am J Case Rep 2023;24:e941992.

Das A, Banerjee A, Tripathy K. Topical moxifloxacin-induced Stevens-Johnson syndrome. J Cataract Refract Surg 2017;43:860-1.

Núñez Ortiz A, Trigo Salado C, de la Cruz Ramírez MD, et al. Topical mesalazine as a cause of Stevens-Johnson syndrome. Rev Esp Enferm Di 2018;110:736-8.

Leitner C. Topical imiquimod—Be aware of the unexpected. JAAD 2016;74:AB223.

Tedman A, Malla U, Vasanthakumar L, et al. Stevens-Johnson syndrome due to topical imiquimod 5%. Aust J Gen Pract 2020;49:662-4.

Trave, I., Salvi, I., Micalizzi, C., Castelli, R., Parodi, A., & Cozzani, E. (2024). Stevens-Johnson induced by imiquimod 5% cream: a case report. Dermatology Reports, 16(4). https://doi.org/10.4081/dr.2024.9930